International LGLL Consortium Publishes Consensus Criteria for Diagnosis, Treatment Initiation and Response Assessment in T-LGL Leukemia

A disease defined differently in every trial

The abstract states the problem the consortium set out to fix: "the absence of uniform diagnostic and response criteria for LGLL results in significant heterogeneity in diagnosis and response assessment across studies." The authors describe LGLL as uncommon and "likely under-diagnosed," a leukemia that "causes severe neutropenia and anemia," is frequently entangled with autoimmune phenomena, and therefore sits across hematology, rheumatology and hematopathology at once.

The consortium describes its output as an evidence-based framework produced by an international panel, intended to "serve as a foundation for both the clinical management and future investigations in LGLL." Its diagnostic section is where pathology laboratories will look first, since the disease is confirmed by the combination of peripheral blood morphology, flow cytometric immunophenotyping, demonstration of T-cell clonality and, in a proportion of cases, STAT3 mutation testing. The exact thresholds, immunophenotypic panels and clonality methods the panel settled on are in the full text, which was behind the ASH paywall when APO|APE News went to press; this article reports only what the freely available abstract and author listing contain, and the specific criteria should be read from the paper itself before they are applied.

Who signed the document

The author list gathers most of the groups that have shaped LGLL research over the past two decades. Thomas P. Loughran of the University of Virginia, Thierry Lamy of Rennes University Hospital, Gianpietro Semenzato and Renato Zambello of Padua, Jaroslaw P. Maciejewski of the Cleveland Clinic, Satu Mustjoki of Helsinki, Fumihiro Ishida of Shinshu University and Pierluigi Porcu of the Sidney Kimmel Cancer Center are all co-authors. The immunophenotyping and clonality side is represented by Julia Almeida of Salamanca, Anton W. Langerak of Erasmus MC and Monika Bruggemann of Kiel. Dima El-Sharkawi of the Royal Marsden, whose 2025 review in Hematological Oncology on separating LGLL from T-cell clones of uncertain significance had already noted that an international consortium "has recently been created with a view to developing consensus guidelines on diagnosis, response assessment and management," is also on the paper.

Trials waiting for a common yardstick

The abstract ties the timing to "the emergence of a variety of novel experimental therapeutics and an increasing number of clinical trials." ClinicalTrials.gov lists several: a study of ruxolitinib in T-LGL leukemia (NCT05592015), a study of siltuximab in LGLL (NCT05316116), a trial of ABC008 in T-LGLL (NCT05532722) and a dose-ranging study of the cytokine inhibitor BNZ-1 in LGL leukemia or refractory cutaneous T-cell lymphoma (NCT03239392). Each of these enrolled and reported under its own definitions of disease and response, which is the situation the consortium wants to close out for the trials that follow.

The nearest model for what the document is trying to do sits in the same journal, which in 2019 published consensus criteria for diagnosis, staging and treatment response assessment of T-cell prolymphocytic leukemia, another rare mature T-cell leukemia that had lacked a shared definition of response. The new report does the same job for T-LGL leukemia seven years later.

Why This Matters to the APO|APE Reader

For a laboratory, the immediate consequence is that a T-LGL diagnosis reported after August 21, 2026 will be measured against a published standard instead of local habit, and the flow, clonality and STAT3 results in the report will need to line up with whatever the consortium specified. For trial sponsors, it removes the excuse that response in LGLL cannot be compared across studies. The document's authority rests on the breadth of its signatories, since no regulator has adopted it; its test will be whether the next generation of T-LGL trial protocols cite it as their entry and endpoint definitions.